Skip to main content

Table 4 HbA1c levels as a function of concomitant diabetes drug use and baseline HbA1c levels

From: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

Medication classification

HbA1c classification

n

Baseline mean ± SD

After administration mean ± SD

Difference

All patients

Total

2086

8.46 ± 1.40

7.71 ± 1.31

-0.76 ± 1.38 §

 
 

7-8%

1010

7.46 ± 0.29

7.20 ± 0.77

-0.25 ± 0.74 §

p < 0.001

 

8-9%

555

8.44 ± 0.28

7.75 ± 1.02

-0.69 ± 1.01 §

 
 

≥9%

521

10.45 ± 1.29

8.64 ± 1.79

-1.81 ± 1.97 §

 

Diabetes drug use

Subtotal

254

7.84 ± 1.04

7.28 ± 1.00

-0.56 ± 1.06 §

 

Before study: not taken

&

7-8%

186

7.38 ± 0.26

7.06 ± 0.67

-0.32 ± 0.66

p < 0.001

During study: not taken

8-9%

46

8.38 ± 0.26

7.64 ± 1.08

-0.74 ± 1,03 §

 
 

≥9%

22

10.64 ± 1.24

8.48 ± 1.85

-2.16 ± 2.03 §

 
 

Subtotal

397

8.89 ± 1.66

7.42 ± 1.36

-1.47 ± 1.88 §

 

Before study: not taken

&

7-8%

147

7.46 ± 0.29

7.06 ± 0.85

-0.39 ± 0.86 §

p < 0.001

During study: taken

8-9%

109

8.45 ± 0.29

7.31 ± 0.96

-1.15 ± 0.97 §

 
 

≥9%

141

10.73 ± 1.40

7.89 ± 1.84

-2.84 ± 2.30 §

 
 

Subtotal

59

8.26 ± 1.33

7.79 ± 1.23

-0.47 ± 1.10 ‡

 

Before study: taken

&

7-8%

34

7.48 ± 0.28

7.26 ± 0.83

-0.22 ± 0.85

p = 0.003

During study: not taken

8-9%

14

8.50 ± 0.28

8.09 ± 1.03

-0.41 ± 0.93

 
 

≥9%

11

10.38 ± 1.67

9.05 ± 1.51

-1.32 ± 1.59 †

 
 

Subtotal

1376

8.46 ± 1.33

7.86 ± 1.31

-0.60 ± 1.20 §

 

Before study: taken

&

7-8%

643

7.48 ± 0.29

7.28 ± 0.76

-0.20 ± 0.73 §

p < 0.001

During study: taken

8-9%

386

8.44 ± 0.27

7.88 ± 1.00

-0.56 ± 0.98 §

 
 

≥9%

347

10.32 ± 1.22

8.94 ± 1.69

-1.38 ± 1.66 §

 
  1. Baseline HbA1c levels for 2086 patients were ≥ 7.0%. A paired t-test was used to assess statistically significant differences from baseline for each group. P values were determined by ANOVA to assess statistically differences from baseline among baseline HbA1c-subgroup